MAPT and Alzheimer disease: In summary, our data reveal that sodium selenate enhances PP2A levels, but reduces catalytic activity in a dose dependent manner (with a maximum effect at 3 μM), which fails to reduce Tau and GSK3β phosphorylation under physiological conditions, indicating an alternative route to rescue of AD pathology.